Atossa Therapeutics, Inc.'s SEC filings document a clinical-stage biopharmaceutical issuer focused on (Z)-endoxifen development in oncology and rare disease settings. Its reports include financial-result 8-Ks, corporate updates, Regulation FD communications, and disclosures tied to research and development spending for its lead product candidate.
The filing record also covers governance and capital-structure matters, including annual meeting votes, director elections, auditor ratification, executive-compensation votes, charter-authority proposals, Form S-3 and at-the-market offering disclosures, Nasdaq listing compliance, and material events involving Endoxifen-related intellectual property proceedings and settlement agreements.
Atossa Therapeutics, Inc. filed a current report describing a strategic update. On September 8, 2025, the company announced a new regulatory strategy intended to accelerate development of its low-dose (Z)-endoxifen product candidate for breast cancer risk reduction. The company furnished a press release with further details as an exhibit to this report.
Atossa Therapeutics, Inc. notified Nasdaq that it was not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid of $1.00 for 30 consecutive business days. The company's initial compliance period ended on August 20, 2025, and after requesting an extension, Nasdaq granted a 180-day extension on August 21, 2025, moving the deadline to regain compliance to February 17, 2026.
Atossa Therapeutics reported widening losses as it advances clinical programs for its lead candidate, oral (Z)-endoxifen. For the six months ended June 30, 2025 the company recorded a $15.1 million net loss and used $13.2 million of cash in operations, compared with $11.9 million and $9.2 million a year earlier. Cash and cash equivalents totaled $57.9 million at June 30, 2025, with working capital of $55.7 million, and management expects this cash to fund operations for at least one year. Total operating expenses rose to $16.5 million for the six-month period driven by higher R&D spending on (Z)-endoxifen trials.
The company highlighted positive clinical signals: low-dose (Z)-endoxifen reduced mammographic breast density (1 mg: 17.3%, 2 mg: 23.5%, both p<0.01) and neoadjuvant and I-SPY 2 data showed tumor suppression and tolerability. Material items to monitor include pending PTAB proceedings challenging two patents (petitions filed by Intas), a non-cancellable clinical commitment of $7.9 million, and a Nasdaq notice requiring the company to regain a $1.00 bid compliance by August 20, 2025.
Atossa Therapeutics, Inc. reported on August 12, 2025 that it issued a press release announcing financial results for the quarter ended June 30, 2025 and providing a company update. The press release is attached as Exhibit 99.1 and the filing includes a cover page Interactive Data File as Exhibit 104. The Company states the information in Items 2.02 and 9.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or subject to certain Securities Act liabilities. This Current Report is signed by Heather Rees, Chief Financial Officer. No numerical financial metrics are included in the 8-K text provided here; consult Exhibit 99.1 for the detailed results and commentary.